Research Finds Potential Way to Expand Melanoma Immunotherapy Benefits

Study Title: Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

Publication: Science Advances

Corresponding author: David Liu, MD, MPH

Summary: Immunotherapy dramatically benefits some patients with metastatic melanoma, but not all. To learn more about the differences, Dana-Farber Cancer Institute investigators and collaborators collected multiple large, high-quality data sets from previous clinical studies into a larger cohort of cases. The data set included patients who were treated with immune checkpoint inhibitors including anti-PD-1, anti-CTLA-4, and combination anti-PD-1 plus anti-CLTA-4, and included pre-treatment tumor sequencing and clinical annotations. The team found that response to therapy was more likely if patient tumors had evidence of infiltration of immune cells into tumors and less likely in tumors with low immune infiltration, sometimes called "cold" tumors. In addition, a lack of oxygen (hypoxia) was associated with resistance to anti-PD-1 therapy in immune-active tumors, but not in immune-cold tumors. The team, in collaboration with investigators at Harvard Medical School, found that an agent that blocks the HIF-2α hypoxia pathway synergizes with anti-PD-1 therapy to control tumor growth in mice with immune-active tumors. A HIF-2α inhibitor called belzutifan is already approved for other conditions and was developed based on the 2019 Nobel Prize winning science by Dana-Farber's William G. Kaelin, MD, PhD.

Significance: Immune checkpoint blockade has dramatically transformed the treatment approach for advanced melanoma, leading to impressive and long-lasting treatment outcomes in a subset of patients. Based on this study, resistance to immunotherapy differs depending on immune activity and identifies hypoxia as a potential biomarker of resistance in immune-high tumors. The findings also point to the potential for HIF-2α inhibition and anti-PD-1 to synergize and expand the benefit of immunotherapy in a subset of patients with metastatic melanoma.

Quote: "These finding suggest that we should study and treat patients with immune-active tumors and immune-cold tumors differently and nominates a potential synergistic treatment regimen in patients with specific tumor characteristics." - Dana-Farber clinician-scientist David Liu, MD, MPH

Funding: American-Italian Cancer Foundation, Society for Immunotherapy of Cancers, Doris Duke Charitable Foundation, National Institutes of Health, Eleanor and Miles Shore, Barr Foundation, Adelson Medical Research Foundation, Bill and Emma Roberts, Patricia the Huiying Foundation, the American Association for Cancer Research (AACR), the Cancer Prevention and Research Institute of Texas.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.